R-MINE regimen
WikiDoc Resources for R-MINE regimen |
Articles |
---|
Most recent articles on R-MINE regimen Most cited articles on R-MINE regimen |
Media |
Powerpoint slides on R-MINE regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on R-MINE regimen at Clinical Trials.gov Trial results on R-MINE regimen Clinical Trials on R-MINE regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on R-MINE regimen NICE Guidance on R-MINE regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on R-MINE regimen Discussion groups on R-MINE regimen Patient Handouts on R-MINE regimen Directions to Hospitals Treating R-MINE regimen Risk calculators and risk factors for R-MINE regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for R-MINE regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Rituximab-Mesna-Ifosfamide-Novantrone-Etoposide regimen
Overview
R-MINE regimen refers to a regimen consisting of rituximab, mesna, ifosfamide, mitoxantrone, and etoposide used to treat relapsed or refractory Hodgkin's lymphoma and non-Hodgkin's lymphoma.[1][2]
Regimen
RRituximab
MMesna
IIfosfamide
NMitoxantrone (Novantrone)
EEtoposide
Indications
References
- ↑ 1.0 1.1 Fan Y, Huang ZY, Luo LH, Yu HF (2005). "[MINE regimen for patients with relapsed or chemo-resistant invasive non-Hodgkin's lymphoma]". Ai Zheng. 24 (12): 1503–6. PMID 16351801.
- ↑ "NCI Thesaurus".
- ↑ "NCI Thesaurus".